Thalidomide: The Drug, the Cover-Up, and the Woman Who Said No

In the late 1950s a German pharmaceutical company began selling a sedative it described as one of the safest drugs ever made. It was gentle, it was effective against the nausea of early pregnancy, and — the company said — it was so free of danger that you could not kill yourself with it if you tried. It was available in West Germany without a prescription. By the time it was withdrawn a few years later, it had caused one of the worst medical catastrophes of the twentieth century, and it had done so while the men responsible for it sat on the warnings. This is the story of a cover-up that was entirely real, and of what happens to a true story about corporate deceit when it hardens, in the retelling, into something simpler and less useful.

Contergan

The drug was thalidomide. The company was Chemie Grünenthal, based near Aachen, and it brought the compound to market in West Germany in 1957 under the trade name Contergan, promoting it as a sedative and sleeping aid. It was soon licensed to companies in dozens of countries — sold in Britain as Distaval by the Distillers Company, and marketed elsewhere across Europe, Australia, Canada and Japan. Part of its appeal was the claim of exceptional safety, and one particular use spread quickly by word of mouth and by prescription: it calmed the nausea and sleeplessness of early pregnancy. Doctors gave it to pregnant women. Women took it in the weeks when they felt most unwell, which are also the weeks in which a baby’s limbs are forming.

The effect, when it came, was unmistakable and terrible. Babies were born with foreshortened or absent limbs, a rare malformation called phocomelia in which the hands or feet emerge close to the body like flippers; many also had damage to internal organs, hearing and sight. Before thalidomide, phocomelia was so rare that most doctors would see none in a career. Now, in the towns where the drug was widely used, paediatricians began seeing it in numbers that had no precedent. Estimates of the toll vary and the true figure will never be exact, but the affected births are generally counted in the region of ten thousand, spread across the countries where the drug was sold, and a large proportion of those children did not survive infancy.

The warnings that were buried

Here is the kernel, the part that is documented and damning: the disaster was not a pure accident of unknowable science. There were warnings, and they were suppressed, minimised and fought.

Two doctors, working independently on opposite sides of the world, made the connection to the drug at almost the same time. In Germany, a paediatrician and geneticist named Widukind Lenz gathered case histories through 1961 and became convinced that thalidomide taken in early pregnancy was the cause. He took his suspicion to Grünenthal in November 1961 and pressed for the drug to be withdrawn. In Australia, an obstetrician named William McBride, seeing the same malformations in his own patients, reached the same conclusion and set out his warning in a short letter to the Lancet in December 1961. The drug was pulled from the German and British markets around the end of that year.

But the record assembled later — through the German criminal investigation, through years of litigation, and through the work of journalists and historians — shows that Grünenthal did not behave like a company caught out by a bolt from the blue. Well before the limb malformations were traced to the drug, the company had been receiving reports of a different serious side effect: peripheral neuritis, a painful and sometimes permanent nerve damage in adults who took thalidomide. The evidence indicates the company played down and resisted these earlier reports rather than acting on them, and that when Lenz raised the alarm about the birth defects, the initial response was defensiveness and delay rather than immediate withdrawal. A drug sold as impossible to overdose on turned out to have been marketed on safety claims the company was not entitled to make, over warning signs it had reason to take seriously.

A long criminal trial of Grünenthal executives in Germany in the late 1960s ended without convictions, settling instead in a way that many of the families found deeply unjust, and the fight for adequate compensation — in Britain, in Germany, and elsewhere — dragged on for decades, in some places into the present century, with formal apologies arriving fifty years too late. In Britain, the campaign fought by the affected families and their supporters, aided by a determined press, eventually forced Distillers into a settlement; the struggle to win it became a landmark in the history of consumer litigation and of press campaigning against a powerful company. The children of the disaster grew into adults who had to argue, decade after decade, for the acknowledgement and the support that should have been theirs by right from the beginning. The slowness of that reckoning is itself part of the cover-up’s long tail: a harm minimised at the moment of its discovery stays minimised, in the ledgers and the courtrooms, for a lifetime. The essential shape is not in serious dispute. A company sold a drug on an overstated promise of safety, was slow to act on evidence of harm, and resisted the reckoning for a generation. That is a corporate cover-up in the plain meaning of the words, and it earned every ounce of the mistrust it created.

The woman who said no

There is one country that was largely spared, and the reason is the human centre of the story. The United States never approved thalidomide for general sale, and it did not because of a single official who declined to be hurried.

Her name was Frances Oldham Kelsey, a physician and pharmacologist who had joined the US Food and Drug Administration in 1960. The application to sell thalidomide in America — under the brand name Kevadon, submitted by the firm Richardson-Merrell — landed on her desk almost as her first assignment. By the standards of the time it looked routine; the drug was already selling widely abroad and the company expected quick approval. Kelsey did not give it. She read the file and found the safety evidence thin. She was troubled in particular by the reports of nerve damage in adult users, and she reasoned that a drug that could damage the nerves of an adult raised unanswered questions about what it might do to a developing baby — questions the application did not address, because almost no one at that time systematically tested drugs for their effects on the foetus. She asked for more data. The company pushed back, repeatedly and with some pressure, and repeatedly she declined to approve until her questions were answered. The application was still pending, held up by her caution, when Lenz and McBride’s warnings broke and the drug was exposed. The delay had kept it off the American market.

For this Kelsey became a national heroine. In 1962 President Kennedy presented her with the President’s Award for Distinguished Federal Civilian Service, and her stand helped drive the Kefauver–Harris Amendment of that year, which for the first time required drug makers to prove a medicine was effective as well as safe before it could be sold. Her caution was real, it was correct, and it spared a great many American families. All of that is true and deserves its honour.

The fork, in two directions

This story forks twice, and both forks are worth walking carefully, because they run in opposite directions.

The first is the fork the myth takes from the corporate cover-up. The documented truth is specific: this company, with this drug, made safety claims it could not support and was slow to act on warnings it had reason to heed. That is a precise, evidenced indictment. The myth flattens it into a general law — that all pharmaceutical companies are lying about all their products, that every drug is a poison and every regulator is bought. The move is understandable and it is wrong in the same way. Thalidomide proves that a drug company can deceive and that vigilance is warranted; it does not prove that every medicine is a thalidomide, any more than one crooked bank proves that money itself is a fraud. The evidenced lesson is that safety must be demonstrated and companies must be watched — which is precisely why the regulatory system was rebuilt after 1962. The overextended lesson throws out the very institutions the disaster called into being.

This is the same overreach that recurs across this desk. A real corporate cover-up earns a real mistrust, and then the mistrust travels further than the evidence can carry it. Big Sugar’s decades of manufacturing doubt genuinely corrupted nutrition science, and that documented deceit is now used to wave away nutritional advice wholesale, as though because industry once lied, nothing about diet can be known. The vaccine–autism myth fed on the same reasonable instinct — do not simply trust what they inject into your child — and steered it toward a claim the evidence flatly refuses. In each case the mistrust has a true origin and a false destination, and the work is to hold the origin without following it to the destination.

The second fork runs the other way, into the hero. The story we tell about Kelsey has smoothed, over the years, into the myth of the lone guardian — one incorruptible woman standing between a rapacious industry and a nation of unborn children, holding the line by sheer virtue. It is a lovely story and it is not quite the true one. Kelsey was cautious and right, and she deserves the credit she is given; but she was not a solitary heroine working against her own agency. She was part of a review system, backed by scientific colleagues who shared her doubts, operating under a law and a professional culture that gave a reviewer the standing to say “not yet”. Her stand mattered enormously, and it was made possible by a structure. The reason this correction is worth making is not to diminish her. It is that the lone-hero version teaches the wrong lesson — that safety depends on finding the occasional saint — when the durable lesson of thalidomide is the opposite: that safety depends on systems, on the boring institutional machinery of required evidence and independent review, precisely so that it does not have to depend on one person’s courage happening to be in the right chair on the right day.

Hold both forks at once and the story keeps its full weight without curdling into either fatalism or fairy tale. The cover-up was real; the mistrust it earned is legitimate; and the answer the disaster produced was not to trust less but to verify better. Thalidomide is why the modern system of drug approval exists in the shape it does — a system built by people who had looked at those children and resolved that safety would never again rest on a company’s word or a single official’s nerve. The tragedy was a betrayal. What was built out of it, at terrible cost, was the machinery meant to make the next betrayal harder. Remembering only the betrayal, and forgetting the machinery, honours neither the children nor the woman who said no.